natgillin/translations-raw huggingface dataset:
In patients with acute ST-segment elevation MI, safety and efficacy of clopidogrel have been evaluated in 2 randomised, placebo-controlled, double-blind studies, CLARITY and COMMIT. 
U bolesnika s akutnim infarktom miokarda s elevacijom ST spojnice (STEMI), sigurnost primjene i djelotvornost klopidogrela procijenjena je u 2 randomizirane, dvostruko-slijepe, placebom kontrolirane studije, CLARITY i COMMIT.
However, the limitations of these data and the uncertainties regarding extrapolation of ex vivo data to the clinical situation imply that no firm conclusions can be made for regular ibuprofen use, and no clinically relevant effect is considered to be likely for occasional ibuprofen use (see section 5.1). 
Međutim, zbog ograničene količine podataka i nesigurnosti u ekstrapolaciji ex vivo podataka u kliničku situaciju, ne mogu se donijeti čvrsti zaključci za redovitu primjenu ibuprofena te se niti jedan klinički značajan učinak ne smatra vjerojatnim kod povremene primjene ibuprofena (vidjeti dio 5.1).
McDermott Laboratories Limited trading as Gerard Laboratories trading as Mylan Dublin, 35/36 Baldoyle Industrial Estate, Grange Road, Dublin 13, Ireland. 
Naziv(i) i adresa(e) proizvođača odgovornog(ih) za puštanje serije lijeka u promet McDermott Laboratories Limited trading as Gerard Laboratories trading as Mylan Dublin, 35/36 Baldoyle Industrial Estate, Grange Road, Dublin 13, Irska.
This benefit was consistent across age, gender and with or without fibrinolytics, and was observed as early as 24 hours. 
Taj učinak je bio dosljedan bez obzira na dob, spol i primjenu fibrinolitika, a opažen je već unutar 24 sata od početka liječenja.
Manufacturers 
Proizvođač
What Clopidogrel/Acetylsalicylic acid Mylan is and what it is used for What you need to know before you take Clopidogrel/Acetylsalicylic acid Mylan How to take Clopidogrel/Acetylsalicylic acid Mylan Possible side effects 
Što je Klopidogrel/acetilsalicilatna kiselina Mylan i za što se koristi Što morate znati prije nego počnete uzimati lijek Klopidogrel/acetilsalicilatna kiselina Mylan Kako uzimati lijek Klopidogrel/acetilsalicilatna kiselina Mylan Moguće nuspojave
In CURE there was no excess in major bleeds with clopidogrel plus ASA within 7 days after coronary bypass graft surgery in patients who stopped therapy more than five days prior to surgery. 
U studiji CURE s klopidogrelom plus ASK nije bilo povećanja broja velikih krvarenja tijekom 7 dana nakon ugrađivanja srčane premosnice u bolesnika koji su lijekove prestali uzimati više od pet dana prije kirurškog zahvata.
• Hypersensitivity to non-steroidal anti-inflammatory drugs (NSAIDs) and syndrome of asthma, rhinitis, and nasal polyps. 
• kod preosjetljivosti na nesteroidne protuupalne lijekove (NSAIL) i sindroma astme, rinitisa i nazalnih polipa.
Follow-up at one year was performed for 316 patients (98.1%) in the de-escalated DAPT group and 318 patients (98.5%) in the unchanged DAPT group. 
Nakon godine dana provedeno je praćenje 316 bolesnika (98,1%) u skupini s de-eskaliranim DAPT-om i 318 bolesnika (98,5%) u skupini s nepromijenjenim DAPT-om.
After a single oral dose of 75 mg, clopidogrel has a half-life of approximately 6 hours. 
Nakon jednokratne oralne doze od 75 mg poluvijek izlučivanja klopidogrela iznosi otprilike 6 sati.
Doses of 500 mg/day and above: 
Doze od 500 mg dnevno i više:
Metamizole may reduce the effect of ASA on platelet aggregation when taken concomitantly. 
Metamizol može smanjiti učinak ASK na agregaciju trombocita kada se istodobno uzimaju.
Consistent with the above results, in a meta-analysis including 6 studies of 335 clopidogrel-treated subjects at steady state, it was shown that active metabolite exposure was decreased by 28% for intermediate metabolisers, and 72% for poor metabolisers while platelet aggregation inhibition (5 μM ADP) was decreased with differences in IPA of 5.9% and 21.4%, respectively, when compared to extensive metabolisers. 
U skladu s gore navedenim rezultatima, u meta analizi koja je uključivala 6 studija s 335 osoba liječenih klopidogrelom u stanju dinamičke ravnoteže, pokazano je da je izloženost aktivnom metabolitu smanjena za 28% za intermedijarne metabolizatore te 72% za spore metabolizatore, dok je inhibicija agregacije trombocita (5 μM ADP) smanjena s razlikama za vrijednosti IPA-e od 5,9%, odnosno 21,4%, u usporedbi s brzim metabolizatorima.
Since clopidogrel is metabolised to its active metabolite partly by CYP2C19, use of medicinal products that inhibit the activity of this enzyme would be expected to result in reduced drug levels of the active metabolite of clopidogrel. 
S obzirom da se klopidogrel djelomično metabolizira u svoj aktivni metabolit pomoću enzima CYP2C19, očekuje se da će primjena lijekova koji inhibiraju aktivnost ovog enzima rezultirati smanjenom razinom aktivnog metabolita klopidogrela.
• methotrexate, a medicine used to treat severe joint disease (rheumatoid arthritis) or skin disease (psoriasis), 
• metotreksat, lijek koji se koristi za liječenje teških bolesti zglobova (reumatoidni artritis) ili bolesti kože (psorijaza),
This medicinal product contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially ‘sodium-free' 
Ovaj lijek sadrži manje od 1 mmol (23 mg) natrija po tableti, tj. zanemarive količine natrija.
Mean peak plasma levels of unchanged clopidogrel (approximately 2.2-2.5 ng/ml after a single 75 mg oral dose) occurred approximately 45 minutes after dosing. 
Prosječna vršna koncentracija nepromijenjenog klopidogrela u plazmi (oko 2,2 - 2,5 ng/ml nakon jednokratne oralne doze od 75 mg), postiže se otprilike 45 minuta nakon uzimanja lijeka.
After repeated doses of 75 mg clopidogrel per day for 10 days in patients with severe hepatic impairment, inhibition of ADP-induced platelet aggregation was similar to that observed in healthy subjects. 
Nakon ponovljenih doza klopidogrela od 75 mg dnevno tijekom deset dana, u bolesnika s teškim oštećenjem funkcije jetre, inhibicija ADP-om inducirane agregacije trombocita bila je slična u usporedbi sa zdravim ispitanicima.
Subsequently a respiratory acidosis occurs as a result of a suppressive effect on the respiratory centre. 
Naknadno, respiratorna acidoza se pojavljuje kao rezultat supresije respiratornog centra.
There is a possible association between acetylsalicylic acid (ASA) and Reye's Syndrome when products containing ASA are given to children or adolescents with a viral infection. 
Postoji sumnja na moguću povezanost između acetilsalicilatne kiseline (ASK) i pojave Reyeovog sindroma, kad se djeci ili adolescentima koji imaju virusnu infekciju daju lijekovi koji sadrže acetilsalicilatnu kiselinu.
• probenecid, benzbromarone, or sulfinpyrazone, medicines used to treat gout, 
• probenecid, benzbromaron ili sulfinpirazon, lijekove koji se primjenjuju za liječenje gihta,
In patients with recent transient ischaemic attack or stroke who are at high risk of recurrent ischaemic events, the combination of ASA and clopidogrel has been shown to increase major bleeding. 
U bolesnika s TIA-om ili moždanim udarom, koji su izloženi visokom riziku rekurentnih ishemijskih događaja, utvrđeno je da kombinacija ASK i klopidogrela pojačava velika krvarenja.
Consider the use of a parenteral antiplatelet agent in acute coronary syndrome patients requiring co-administration of morphine or other opioid agonists. 
Potrebno je razmotriti primjenu parenteralnog antitrombocitnog lijeka u bolesnika s akutnim koronarnim sindromom kod kojih se mora istodobno primijeniti morfin ili drugi agonisti opioida.
The CLARITY trial included 3,491 patients presenting within 12 hours of the onset of a ST elevation MI and planned for thrombolytic therapy. 
Studija CLARITY uključivala je 3491 bolesnika, koji su unutar posljednjih 12 sati doživjeli infarkt miokarda s elevacijom ST-spojnice i planirala im se trombolitička terapija.
• Alcohol may increase the risk of gastrointestinal injury when taken with ASA. 
• Alkohol može povećati rizik od gastrointestinalnog oštećenja kad se uzima s ASK.
Interactions with the following medicinal products with higher (anti-inflammatory) doses of ASA have also been reported: angiotensin converting enzyme (ACE) inhibitors, phenytoin, beta blockers, diuretics, and oral hypoglycemic agents. 
Također su prijavljene interakcije za visoku (protuupalnu) dozu ASK i sljedeće lijekove: inhibitori angiotenzin konvertirajućeg enzima (ACE inhibitori), fenitoin, beta blokatori, diuretici i oralni hipoglikemici.
Film coated tablet (tablet) 
Filmom obložena tableta (tableta).
However, the limitations of these data and the uncertainties regarding extrapolation of ex vivo data to the clinical situation imply that no firm conclusions can be made for regular ibuprofen use, and no clinically relevant effect is considered to be likely for occasional ibuprofen use. 
Međutim, zbog ograničene količine podataka i nesigurnosti ekstrapolacije ex vivo podataka u kliničku situaciju, ne mogu se donijeti čvrsti zaključci za redovitu primjenu ibuprofena te se niti jedan klinički značajan učinak ne smatra vjerojatnim kod povremene uporabe ibuprofena.
If a dose is missed: - Within less than 12 hours after regular scheduled time: patients should take the dose immediately and then take the next dose at the regular scheduled time. 
Propuštena doza: - ako je prošlo manje od 12 sati nakon uobičajenog termina uzimanja lijeka: bolesnik treba odmah uzeti dozu, a sljedeću dozu bolesnik treba uzeti prema uobičajenom rasporedu.
Clopidogrel/Acetylsalicylic acid Mylan is taken by adults to prevent blood clots forming in hardened arteries which can lead to atherothrombotic events (such as stroke, heart attack, or death). 
Lijek Klopidogrel/acetilsalicilatna kiselina Mylan uzimaju odrasli za sprječavanje stvaranja krvnih ugrušaka (tromba) u zadebljanim arterijama, što može dovesti do aterotrombotičkih događaja (kao što su moždani udar, srčani udar ili smrt).
Clopidogrel/Acetylsalicylic acid Mylan is not intended for use in children or adolescents less than 18 years of age. 
Lijek Klopidogrel/acetilsalicilatna kiselina Mylan nije namijenjen liječenju djece ili adolescenata mlađih od 18 godina.
Bleeding events defined as all BARC occurred in 30 patients (9.3%) in the deescalated DAPT group and in 76 patients (23.5%) in the unchanged DAPT group (p<0.01). 
Događaji krvarenja definirani kao svi BARC stupnjevi dogodili su se u 30 bolesnika (9,3%) u skupini s de-eskaliranim DAPT-om i u 76 bolesnika (23,5%) u skupini s nepromijenjenim DAPT-om (p<0,01).
The active metabolite of clopidogrel selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet P2Y12 receptor and the subsequent ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation. 
Aktivni metabolit klopidogrela selektivno inhibira vezanje adenozin difosfata (ADP) za njegov receptor P2Y12 na trombocitima te posljedično ADP-om posredovano aktiviranje glikoprotein kompleksa GPIIb/IIIa, sprečavajući tako agregaciju trombocita.
Overall clopidogrel 75 mg/day was similar to ASA 325 mg/day in CAPRIE regardless of age, gender and race. 
Sveukupno su, u studiji CAPRIE, podaci za klopidogrel u dozi od 75 mg/dan bili slični podacima za ASK u dozi od 325 mg/dan, bez obzira na dob, spol ili rasu.
Driving and using machines Clopidogrel/Acetylsalicylic acid Mylan should not affect your ability to drive or to use machines. 
Lijek Klopidogrel/acetilsalicilatna kiselina Mylan ne bi trebao utjecati na Vašu sposobnost upravljanja vozilima ili strojevima.
A significantly lower exposure to clopidogrel active metabolite and reduced platelet inhibition have been demonstrated in HIV-infected patients treated with ritonavir- or cobicistat-boosted anti-retroviral therapies. 
Znatno niža izloženost aktivnom metabolitu klopidogrela i smanjena inhibicija trombocita pokazane su kod bolesnika zaraženih virusom HIV liječenih antiretrovirusnim lijekovima pojačanih ritonavirom i kobicistatom.
The primary endpoint was the occurrence of the composite of an occluded infarct-related artery on the pre- discharge angiogram, or death or recurrent MI before coronary angiography. 
Primarni ishod bio je pojava okludirane koronarne arterije povezane s infarktom miokarda na angiogramu učinjenom prije otpusta, smrt, ili rekurentni infarkt miokarda prije koronarne angiografije.
The CURE study included 12,562 patients with non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), and presenting within 24 hours of onset of the most recent episode of chest pain or symptoms consistent with ischaemia. 
Studija CURE uključivala je 12 562 bolesnika s akutnim koronarnim sindromom bez elevacije ST segmenta (nestabilna angina ili non-Q infarkt miokarda), koji su u zadnja 24 sata imali epizodu boli u prsištu ili simptome ishemije.
At very high doses, a poor gastric tolerability (gastritis, gastric erosions and/or vomiting) of clopidogrel was also reported in rat and baboon. 
Pri vrlo visokim dozama također je zabilježena slaba želučana podnošljivost klopidogrela (gastritis, erozije želuca i/ili povraćanje) u štakora i babuna.
Clopidogrel active metabolite pharmacokinetics and antiplatelet effects, as measured by ex vivo platelet aggregation assays, differ according to CYP2C19 genotype. 
Farmakokinetika i antitrombocitni učinak aktivnog metabolita klopidogrela, mjereni u ex vivo ispitivanjima agregacije trombocita, razlikuju se ovisno o genotipu CYP2C19.
You have been prescribed Clopidogrel/Acetylsalicylic acid Mylan in place of the two separate medicines, clopidogrel and ASA, to help prevent blood clots because you have experienced a severe type of chest pain known as ‘unstable angina' or heart attack (myocardial infarction). 
Klopidogrel/acetilsalicilatna kiselina Mylan Vam je propisan u zamjenu za dva odvojena lijeka, klopidogrel i ASK, u svrhu sprječavanja stvaranja krvnih ugrušaka jer ste imali teški oblik boli u prsnom košu, koji je poznat pod nazivom „nestabilna angina” ili ste imali srčani udar (infarkt miokarda).
Acute liver failure, liver injury, mainly hepatocellular*, hepatitis, elevation of hepatic enzymes*, abnormal liver function test, chronic hepatitis* 
Poremećaji jetre i žuči akutno zatajenje jetre, ozljeda jetre, uglavnom hepatocelularna*, hepatitis, povišenje jetrenih enzima*, abnormalni nalazi jetrene funkcije, kronični hepatitis*
• In patients with gout since low doses of ASA increase urate concentrations. 
• u bolesnika koji boluju od gihta, jer niske doze ASK mogu povećati koncentraciju urata,
• You should also tell your doctor immediately if you develop a medical condition known as Thrombotic Thrombocytopenic Purpura or TTP that includes fever and bruising under the skin that may appear as red pinpoint dots, with or without unexplained extreme tiredness, confusion, yellowing of the skin or eyes (jaundice) (see section 4). 
• Odmah obavijestite svog liječnika ukoliko se pojavi bolest poznata kao trombotična trombocitopenična purpura ili TTP sa simptomima koji uključuju vrućicu i potkožne hematome koji se mogu pojaviti kao crvene točkice, s ili bez neobjašnjivog teškog umora, smetenosti i žute boje kože ili očiju (žutica) (vidjeti dio 4.).
More than 30,000 patients entered into clinical trials with clopidogrel plus ASA at maintenance doses lower than or equal to 325 mg, and received a variety of concomitant medicinal products including diuretics, beta blockers, ACE Inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions. 
Više od 30 000 bolesnika sudjelovalo je u kliničkim ispitivanjima u kojima su, uz klopidogrel i ASK u dozama održavanja jednakim ili manjim od 325 mg, primali niz istodobno primijenjenih različitih lijekova uključujući diuretike, beta-blokatore, ACE inhibitore, antagoniste kalcija, lijekove koji snižavaju razinu kolesterola, koronarne vazodilatatore, antidijabetike (uključujući inzulin), antiepileptike i GPIIb/IIIa antagoniste, bez dokaza klinički značajnih štetnih interakcija.
Clopidogrel/Acetylsalicylic acid Mylan is indicated for the secondary prevention of atherothrombotic events in adult patients already taking both clopidogrel and acetylsalicylic acid (ASA). 
Klopidogrel/acetilsalicilatna kiselina Mylan je indicirana za sekundarnu prevenciju aterotrombotičnih događaja u odraslih bolesnika koji već uzimaju klopidogrel i acetilsalicilatnu kiselinu (ASK).
Non-cardiogenic pulmonary edema can occur with acute and chronic acetylsalicylic acid overdose (see section 4.8). 
Nekardiogeni edem pluća može se javiti pri akutnom i kroničnom predoziranju acetilsalicilatnom kiselinom (vidjeti dio 4.8).
This statistically significant difference was mainly driven by fewer bleeding events, with no difference reported in ischaemic endpoints (p=0.36), while BARC ≥2 bleeding occurred less frequently in the de-escalated DAPT group (4.0%) versus 14.9% in the unchanged DAPT group (p<0.01). 
Ova statistički značajna razlika uglavnom je posljedica manjeg broja događaja krvarenja, bez prijavljene razlike u ishemijskim mjerama ishoda (p=0,36), dok se BARC stupanj krvarenja ≥ 2 javljao rjeđe u skupini s de-eskaliranim DAPT-om (4,0%) u odnosu na skupinu s nepromijenjenim DAPT-om (p<0,01).
Caution is recommended when co-administering salicylates with acetazolamide as there is an increased risk of metabolic acidosis. 
Preporučen je oprez pri istodobnoj primjeni salicilata i acetazolamida zbog povećanog rizika od metaboličke acidoze.
Data from the CAPRIE study indicate that phenytoin and tolbutamide which are metabolised by CYP2C9 can be safely co-administered with clopidogrel. 
Podaci iz studije CAPRIE pokazuju da je istodobna primjena fenitoina i tolbutamida, koji se metaboliziraju pomoću CYP2C9, s klopidogrelom sigurna.
• valproic acid, valproate or carbamazepine, medicines to treat some forms of epilepsy, 
• valproatnu kiselinu, valproat ili karbamazepin, lijekove koji se primjenjuju za liječenje nekih oblika epilepsije,
Clopidogrel/Acetylsalicylic acid Mylan should be used with caution in patients with a history of peptic ulcer or gastroduodenal haemorrhage or minor upper GI symptoms as this may be due to gastric ulceration which may lead to gastric bleeding. 
Klopidogrel/acetilsalicilatna kiselina Mylan treba se primjenjivati s oprezom u bolesnika koji u anamnezi imaju peptički ulkus ili gastroduodenalno krvarenje ili manje simptome u gornjem dijelu gastrointestinalnog trakta, budući da mogu biti posljedica želučanih ulceracija i dovesti do želučanog krvarenja.
- For more than 12 hours: patients should take the next dose at the regular scheduled time and should not double the dose. 
- ako je prošlo više od 12 sati nakon uobičajenog termina uzimanja lijeka: bolesnik treba uzeti sljedeću dozu prema uobičajenom rasporedu i ne smije uzeti dvostruku dozu.
Alcohol may increase the risk of gastrointestinal injury when taken with ASA. 
Alkohol može povećati rizik od gastrointestinalnog oštećenja kad se uzima s ASK.
Therefore, the guided de-escalation arm had patients on either prasugrel (40%) or clopidogrel (60%). 
Dakle, u skupini s deeskalacijom vođenoj na temelju vrijednosti HPR-a, bolesnici su primali ili prasugrel (40%) ili klopidogrel (60%).
It is characterised by thrombocytopenia and microangiopathic haemolytic anaemia associated with either neurological findings, renal dysfunction or fever. 
Karakteriziraju je trombocitopenija i mikroangiopatska hemolitička anemija kojima mogu biti pridruženi neurološki simptomi, poremećaj funkcije bubrega ili vrućica.
Clopidogrel/Acetylsalicylic acid Mylan contains clopidogrel and acetylsalicylic acid (ASA) and belongs to a group of medicines called antiplatelet medicinal products. 
Klopidogrel/acetilsalicilatna kiselina Mylan sadrži klopidogrel i acetilsalicilatnu kiselinu (ASK) i pripada skupini lijekova koji se nazivaju antitrombocitni lijekovi.
Subsequent metabolism of the 2-oxo-clopidogrel intermediate metabolite results in formation of the active metabolite, a thiol derivative of clopidogrel. 
Naknadni metabolizam intermedijarnog metabolita 2-okso-klopidogrela rezultira nastajanjem aktivnog metabolita, tiolnog derivata klopidogrela.
• if you have kidney or liver disease. 
• ako imate bolest jetre ili bubrega.
If you have any further questions, ask your doctor, or pharmacist. 
- Ako imate dodatnih pitanja, obratite se liječniku ili ljekarniku.
Concomitant administration of tenofovir disoproxil fumarate and NSAIDs may increase the risk of renal failure. 
Istodobna primjena tenofovirdizoproksilfumarata i NSAIL-ova može povećati rizik od zatajenja bubrega.
Varicella vaccine 
Cjepivo protiv varičela
Following absorption, the ASA in Clopidogrel/Acetylsalicylic acid Mylan is hydrolysed to salicylic acid with peak plasma levels of salicylic acid occurring within 1 hour of dosing, such that plasma levels of ASA are essentially undetectable 1.5-3 hours after dosing. 
Nakon apsorpcije, ASK iz lijeka Klopidogrel/acetilsalicilatna kiselina Mylan se hidrolizira u salicilatnu kiselinu čija se vršna koncentracija u plazmi pojavljuje unutar jednog sata od primjene, tako da je koncentraciju ASK u plazmi gotovo nemoguće odrediti poslije 1,5 do 3 sata nakon doziranja.
Do not take Clopidogrel/Acetylsalicylic acid Mylan during third trimester of pregnancy. 
Nemojte uzimati lijek Klopidogrel/acetilsalicilatna kiselina Mylan u trećem tromjesečju trudnoće.
Co-administration of heparin had no effect on the inhibition of platelet aggregation induced by clopidogrel. 
Istodobna primjena heparina nije djelovala na inhibiciju agregacije trombocita induciranu klopidogrelom.
A crossover study in 40 healthy subjects, 10 each in the four CYP2C19 metaboliser groups (ultrarapid, extensive, intermediate and poor), evaluated pharmacokinetic and antiplatelet responses using 300 mg followed by 75 mg/day and 600 mg followed by 150 mg/day, each for a total of 5 days (steady state). 
U križnoj studiji na 40 zdravih ispitanika, po 10 iz svake od 4 skupine CYP2C19 metabolizatora (vrlo brzi, brzi, intermedijarni i spori), procijenjen je farmakokinetički i antitrombocitni odgovor upotrebom doze od 300 mg, nakon čega je slijedila doza od 75 mg/dan te doze od 600 mg, nakon čega je slijedila doza od 150 mg/dan, u trajanju od ukupno 5 dana (stanje dinamičke ravnoteže).
Based on the pharmacokinetic and metabolic characteristics of both compounds, clinically significant PK interactions are unlikely. 
S obzirom na farmakokinetička i metabolička svojstva obje djelatne tvari, nije vjerojatna pojava klinički značajnih farmakokinetičkih interakcija.
Contact your doctor before stopping or restarting your treatment. 
Prije prekida ili ponovnog početka terapije kontaktirajte svog liječnika.
Therefore, concomitant use should be undertaken with caution (see section 4.4). 
Zbog toga je pri istodobnoj primjeni potreban oprez (vidjeti dio 4.4).
28 film-coated tablets 30 film-coated tablets 
28 filmom obloženih tableta 30 filmom obloženih tableta
Elimination Following an oral dose of 
Nakon primjene oralne doze
Colitis (including ulcerative or lymphocytic colitis), stomatitis, acute pancreatitis in the context of a hypersensitivity reaction due to acetylsalicylic acid* 
Kolitis (uključujući ulcerozni ili limfocitni kolitis), stomatitis, akutni pankreatitis u kontekstu reakcije preosjetljivosti na acetilsalicilatnu kiselinu*
• swelling in the mouth or skin disorders such as rashes and itching, blisters of the skin. 
• oticanje u ustima ili kožne poremećaje kao što su osip i svrbež te mjehurići na koži.
The lethal dose of acetylsalicylic acid is 25-30 g. Plasma salicylate concentrations above 300 mg/l (1.67 mmol/l) suggest intoxication. 
Koncentracija salicilata u plazmi iznad 300 mg/l (1,67 mmol/l) upućuje na intoksikaciju.
Breast-feeding should be discontinued during treatment with Clopidogrel/Acetylsalicylic acid Mylan. 
Dojenje treba prekinuti za vrijeme liječenja lijekom Klopidogrel/acetilsalicilatna kiselina Mylan.
ASA is known to be excreted in limited amounts in human milk. 
Poznato je da se u ljudi ASK, u ograničenim količinama, izlučuje u majčino mlijeko.